Mycobacterium chelonae: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) |
Shanshan Cen (talk | contribs) |
||
| Line 27: | Line 27: | ||
===Antimicrobial regimen=== | ===Antimicrobial regimen=== | ||
*1.''' Localized infections''' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref> | *1.''' Localized infections''' <ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref> | ||
:* Preferred regimen: [[Clarithromycin]] 500 mg PO | :* Preferred regimen: [[Clarithromycin]] 500 mg PO BID | ||
:* Alternative regimen: [[Azithromycin]] | :* Alternative regimen: [[Azithromycin]] | ||
*2. '''Disseminated or extensive disease''' | *2. '''Disseminated or extensive disease''' | ||
:*2.1 monotherapy | :*2.1 monotherapy | ||
::* Preferred regimen: [[Clarithromycin]] 500 mg PO | ::* Preferred regimen: [[Clarithromycin]] 500 mg PO BID | ||
:*2.2 multidrug therapy | :*2.2 multidrug therapy | ||
::* preferred regimen: [[Clarithromycin]] 500 mg PO BID {{and}} [[Tobramycin]] 5 mg IV/kg/day {{or}} [[Imipenem]] 0.5-1 g IV q6h {{or}} [[Linezolid]] 600 mg IV/PO BID for 4-8 weeks | ::* preferred regimen: [[Clarithromycin]] 500 mg PO BID {{and}} [[Tobramycin]] 5 mg IV/kg/day PO {{or}} [[Imipenem]] 0.5-1 g IV q6h {{or}} [[Linezolid]] 600 mg IV/PO BID for 4-8 weeks | ||
::* Alternative regimen: [[Moxifloxacin]] 400 mg | ::* Alternative regimen: [[Moxifloxacin]] 400 mg PO qd {{and}} [[Linezolid]] 600 mg PO BID | ||
:* NOTE: Total treatment duration is 6 months | :* NOTE: Total treatment duration is 6 months | ||
*3. '''Keratitis (LASIK-related)''' | *3. '''Keratitis (LASIK-related)''' | ||
:* Preferred regimen: [[Clarithromycin]] 500 mg PO BID {{and}} topicals ([[Tobramycin]] 0.3%, 2 gtts q4h {{and}} [[Gatifloxacin]] 0.3%, 1 gtt q4h {{or}} [[Moxifloxacin]] 0.5%, 1 gtt q4h | :* Preferred regimen: [[Clarithromycin]] 500 mg PO BID {{and}} topicals ([[Tobramycin]] 0.3%, 2 gtts q4h {{and}} [[Gatifloxacin]] 0.3%, 1 gtt q4h {{or}} [[Moxifloxacin]] 0.5%, 1 gtt q4h | ||
==References== | ==References== | ||
Revision as of 14:32, 15 July 2015
| style="background:#Template:Taxobox colour;"|Mycobacterium chelonae | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| style="background:#Template:Taxobox colour;" | Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Mycobacterium chelonae Bergey et al. 1923, ATCC 35752 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Overview
Mycobacterium chelonae is a species of the phylum actinobacteria (Gram-positive bacteria with high guanine and cytosine content, one of the dominant phyla of all bacteria), belonging to the genus mycobacterium.
Mycobacterium chelonae is a rapidly growing mycobacterium, that is found all throughout the environment including sewage and tap water. It can occasionally cause opportunistic infections of humans.
It is grouped in Runyon group IV.
Type strain: strain CM 6388 = ATCC 35752 = CCUG 47445 = CIP 104535 = DSM 43804 = JCM 6388 = NCTC 946.
Treatment
Antimicrobial regimen
- 1. Localized infections [1]
- Preferred regimen: Clarithromycin 500 mg PO BID
- Alternative regimen: Azithromycin
- 2. Disseminated or extensive disease
- 2.1 monotherapy
- Preferred regimen: Clarithromycin 500 mg PO BID
- 2.2 multidrug therapy
- preferred regimen: Clarithromycin 500 mg PO BID AND Tobramycin 5 mg IV/kg/day PO OR Imipenem 0.5-1 g IV q6h OR Linezolid 600 mg IV/PO BID for 4-8 weeks
- Alternative regimen: Moxifloxacin 400 mg PO qd AND Linezolid 600 mg PO BID
- NOTE: Total treatment duration is 6 months
- 3. Keratitis (LASIK-related)
- Preferred regimen: Clarithromycin 500 mg PO BID AND topicals (Tobramycin 0.3%, 2 gtts q4h AND Gatifloxacin 0.3%, 1 gtt q4h OR Moxifloxacin 0.5%, 1 gtt q4h
References
- ↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.